Immunologic Research

, Volume 67, Issue 1, pp 151–156 | Cite as

Positive correlation between interleukin-1 receptor antagonist gene 86bp VNTR polymorphism and colorectal cancer susceptibility: a case-control study

  • Mostafa Ibrahimi
  • Maryam Moossavi
  • Ehsan Nazemalhosseini Mojarad
  • Mahsa Musavi
  • Milad Mohammadoo-khorasaniEmail author
  • Zahra ShahsavariEmail author
Original Article


Colorectal cancer (CRC) is one of the most common malignancies worldwide. Genetic variations in cytokine genes and their receptors lead to the severity of the disease. The interleukin-1 receptor antagonist (IL1RN) is a cytokine that inhibits interleukin-1 (IL-1) activity by binding to IL-1 receptors. Also, interleukin-4 (IL-4) is an anti-inflammatory cytokine that can play an important role in several cancers. The present case-control study was aimed to evaluate the association of IL-4 and IL1RN VNTR polymorphisms with the susceptibility to CRC in a sample of Iranian population provided by the Research Center for Gastroenterology and Liver Disease at Taleghani Hospital, Tehran. A total of 123 patients diagnosed with CRC and 152 healthy controls were recruited in the present study. Genomic DNA was extracted by salting out method from whole blood and genotyping of IL1RN and IL-4 VNTR polymorphisms were determined by PCR-based technology. Our study manifested the frequency of 1/2 and 2/4 genotypes of IL1RN 68bp VNTR polymorphism are significantly different between both groups (p = 0.0001 and p = 0.01 respectively). However, we could not find any correlation between IL-4 VNTR polymorphism and CRC cancer. It seems that 1/2 and 2/4 genotypes of IL1RN are correlated with CRC susceptibility in our population, although, more studies are needed to confirm our results.


Colorectal cancer Cytokines VNTR polymorphism IL-4 IL1RN 


Funding information

The authors thank Shahid Beheshti University of Medical Sciences Deputy of Research Affairs for funding this project (p/25/14/605).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. 2016;13(1):120–35.CrossRefGoogle Scholar
  2. 2.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefGoogle Scholar
  3. 3.
    Rafiemanesh H, Pakzad R, Abedi M, Kor Y, Moludi J, Towhidi F, et al. Colorectal cancer in Iran: epidemiology and morphology trends. EXCLI J. 2016;15:738.Google Scholar
  4. 4.
    Shadmani FK, Ayubi E, Khazaei S, Sani M, Hanis SM, Khazaei S et al. Geographic distribution of the incidence of colorectal cancer in Iran: a population-based study. Epidemiol Health 2017;39.Google Scholar
  5. 5.
    Dolatkhah R, Somi MH, Kermani IA, Ghojazadeh M, Jafarabadi MA, Farassati F, et al. Increased colorectal cancer incidence in Iran: a systematic review and meta-analysis. BMC Public Health. 2015;15(1):997.CrossRefGoogle Scholar
  6. 6.
    Brenner DR, Scherer D, Muir K, Schildkraut J, Boffetta P, Spitz MR et al. A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Prev Biomarkers. 2014:cebp 0064.2014.Google Scholar
  7. 7.
    Mager LF, Wasmer M-H, Rau TT, Krebs P. Cytokine-induced modulation of colorectal cancer. Front Oncol. 2016;6.Google Scholar
  8. 8.
    Stubljar D, Jeverica S, Jukic T, Skvarc M, Pintar T, Tepes B, et al. The influence of cytokine gene polymorphisms on the risk of developing gastric cancer in patients with Helicobacter pylori infection. Radiol Oncol. 2015;49(3):256–64.CrossRefGoogle Scholar
  9. 9.
    Gupta MK, Singh R, Banerjee M. Cytokine gene polymorphisms and their association with cervical cancer: a North Indian study. Egypt J Med Human Gen. 2016;17(2):155–63.CrossRefGoogle Scholar
  10. 10.
    Marszałek A, Szylberg Ł, Wiśniewska E, Janiczek M. Impact of COX-2, IL-1β, TNF-α, IL-4 and IL-10 on the process of carcinogenesis in the large bowel. Pol J Pathol. 2012;63(4):221–7.CrossRefGoogle Scholar
  11. 11.
    Mohammadoo-Khorasani M, Salimi S, Tabatabai E, Sandoughi M, Zakeri Z, Farajian-Mashhadi F. Interleukin-1β (IL-1β) & IL-4 gene polymorphisms in patients with systemic lupus erythematosus (SLE) & their association with susceptibility to SLE. Indian J Med Res. 2016;143(5):591–6.CrossRefGoogle Scholar
  12. 12.
    Olver S, Apte S, Baz A, Kienzle N. The duplicitous effects of interleukin 4 on tumour immunity: how can the same cytokine improve or impair control of tumour growth? HLA. 2007;69(4):293–8.Google Scholar
  13. 13.
    Salimi S, Mohammadoo-Khorasani M, Yaghmaei M, Mokhtari M, Moossavi M. Possible association of IL-4 VNTR polymorphism with susceptibility to preeclampsia. Biomed Res Int. 2014;2014:1–5.Google Scholar
  14. 14.
    Viet HT, Wågsäter D, Hugander A, Dimberg J. Interleukin-1 receptor antagonist gene polymorphism in human colorectal cancer. Oncol Rep. 2005;14(4):915–8.Google Scholar
  15. 15.
    Patterson D, Jones C, Hart I, Bleskan J, Berger R, Geyer D, et al. The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. Genomics. 1993;15(1):173–6.CrossRefGoogle Scholar
  16. 16.
    Tarlow JK, Blakemore AI, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet. 1993;91(4):403–4.CrossRefGoogle Scholar
  17. 17.
    El-Omar EM, Carrington M, Chow W-H, McColl KE, Bream JH, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404(6776):398–402.CrossRefGoogle Scholar
  18. 18.
    Zhang Y, Liu C, Peng H, Zhang J, Feng Q. IL1 receptor antagonist gene IL1-RN variable number of tandem repeats polymorphism and cancer risk: a literature review and meta-analysis. PLoS One. 2012;7(9):e46017.CrossRefGoogle Scholar
  19. 19.
    Kok Y-Y, Ong H-H, Say Y-H. Interleukin-1 receptor antagonist and interleukin-4 genes variable number tandem repeats are associated with adiposity in Malaysian subjects. J Obes. 2017;2017:1–8.CrossRefGoogle Scholar
  20. 20.
    Ma J, Sun X, Guo T, Su H, Chen Q, Gong Z, et al. Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell. Cancer Manag Res. 2017;9:481–93.CrossRefGoogle Scholar
  21. 21.
    Jahantigh D, Salimi S, Mousavi M, Moossavi M, Mohammadoo-Khorasani M, Narooei-nejad M, et al. Association between functional polymorphisms of DNA double-strand breaks in repair genes XRCC5, XRCC6 and XRCC7 with the risk of systemic lupus erythematosus in South East Iran. DNA Cell Biol. 2015;34(5):360–6.CrossRefGoogle Scholar
  22. 22.
    Salimi S, Mohammadoo-Khorasani M, Mousavi M, Yaghmaei M, Mokhtari M, Farajian-Mashhadi F. Association of interleukin-1 receptor antagonist VNTR polymorphism and risk of pre-eclampsia in southeast Iranian population. J Obstet Gynaecol Res. 2016;42(2):142–7.CrossRefGoogle Scholar
  23. 23.
    Bredberg A. Cancer: more of polygenic disease and less of multiple mutations? A quantitative viewpoint. Cancer. 2011;117(3):440–5.CrossRefGoogle Scholar
  24. 24.
    Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology—analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol. 2011;8(12):711–9.CrossRefGoogle Scholar
  25. 25.
    Duan Y, Pan C, Shi J, Chen H, Zhang S. Association between interleukin-4 gene intron 3 VNTR polymorphism and cancer risk. Cancer Cell Int. 2014;14(1):131.CrossRefGoogle Scholar
  26. 26.
    Hughes LA, Simons CC, van den Brandt PA, van Engeland M, Weijenberg MP. Lifestyle, diet, and colorectal cancer risk according to (epi) genetic instability: current evidence and future directions of molecular pathological epidemiology. Curr Colorectal Cancer Rep. 2017;13(6):455–69.CrossRefGoogle Scholar
  27. 27.
    Ogino S, Chan AT, Fuchs CS, Giovannucci E. Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397–411.CrossRefGoogle Scholar
  28. 28.
    Gopal M. Role of cytokines in tumor immunity and immune tolerance to cancer. Cancer immunology. Springer; 2015. p. 93–119.Google Scholar
  29. 29.
    Yigit M, Değirmencioğlu S, Ugurlu E, Yaren A. Effect of serum interleukin-1 receptor antagonist level on survival of patients with non-small cell lung cancer. Molecular and Clinical Oncology. 2017;6(5):708–12.CrossRefGoogle Scholar
  30. 30.
    Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res. 2012;72(24):6338–43.CrossRefGoogle Scholar
  31. 31.
    Ahmed AB, Zidi S, Ghazouani E, Mezlini A, Lagha A, Bouraoui S et al. Interleukin-1 receptor antagonist VNTR polymorphism and ovarian cancer susceptibility in Tunisian women. 2014.Google Scholar
  32. 32.
    Yang C-M, Chen H-C, Hou Y-Y, Lee M-C, Liou H-H, Huang S-J, et al. A high IL-4 production diplotype is associated with an increased risk but better prognosis of oral and pharyngeal carcinomas. Arch Oral Biol. 2014;59(1):35–46.CrossRefGoogle Scholar
  33. 33.
    Bhayal AC, Krishnaveni D, Rao KPR, Kumar AR, Jyothy A, Nallari P, et al. Significant association of interleukin4 intron 3 VNTR polymorphism with susceptibility to gastric cancer in a South Indian population from Telangana. PLoS One. 2015;10(9):e0138442.CrossRefGoogle Scholar
  34. 34.
    Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131–42.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical BiochemistryTarbiat Modares UniversityTehranIran
  2. 2.Department of Molecular MedicineBirjand University of Medical SciencesBirjandIran
  3. 3.Student Research CommitteeBirjand University of Medical SciencesBirjandIran
  4. 4.Gastroenterology and Liver Disease Research CenterShahid Beheshti University of Medical SciencesTehranIran
  5. 5.Department of Biostatistics and EpidemiologyHamadan University of Medical SciencesHamadanIran
  6. 6.Faculty of Paramedical SciencesShahid Beheshti University of Medical SciencesTehranIran

Personalised recommendations